Search form
Search
contact us
Navigation
home
boards
Jobs
job ratings
cp wire
medtech news
pharmagather
catering
advertise
whistleblower info
pharmaceutical fraud
medical device | DME fraud
clinical lab fraud
False Claims Act
Legal Help
login/register
You are here
Home
» Novartis CEO's Dilemma: Is $475,000 Too Much For A Leukemia Breakthrough? Or Is It Not Enough?
Novartis CEO's Dilemma: Is $475,000 Too Much For A Leukemia Breakthrough? Or Is It Not Enough?
Novartis CEO's Dilemma: Is $475,000 Too Much For A Leukemia Breakthrough? Or Is It Not Enough?
Submitted by
admin
on August 30, 2017 - 11:53pm
Source:
Forbes
News Tags:
Novartis
CAR-T
drug pricing
FDA
acute lymphoblastic leukemia
Kymriah
Joe Jimenez
Headline:
Novartis CEO's Dilemma: Is $475,000 Too Much For A Leukemia Breakthrough? Or Is It Not Enough?
Do Not Allow Advertisers to Use My Personal information
